At a glance
| Field | Details |
|---|---|
| Brand names | Trulicity |
| Targets | GLP-1R |
| Developer | Eli Lilly |
| Modality | SC injection, once-weekly |
| Approval status | Approved — US 2014 |
| Key efficacy | ~3kg weight loss; HbA1c -1.1–1.4% (AWARD trials) |
| Indications | Type 2 diabetes, cardiovascular risk reduction |
User Sentiment
Trulicity has a loyal base — patients who've been on it for years report it as reliable and low-drama. The hidden-needle autoinjector gets consistent praise from people who are anxious about injections. The main sentiment shift has been awareness that tirzepatide produces meaningfully more weight loss.
Example(What the community says)
r/diabetes threads about Trulicity are mostly long-timers sharing stable experiences. New patients asking for comparisons are often pointed toward tirzepatide — which Lilly also makes. The most consistent praise for dulaglutide: the pen. People who were scared of needles report the click-and-done design made self-injection feel manageable for the first time.
How it works
A GLP-1 analog fused to an Fc antibody fragment — the Fc domain extends half-life to approximately 5 days, enabling once-weekly dosing. Structurally distinct from semaglutide's albumin-binding approach but achieving the same pharmacokinetic goal. The Fc fusion also reduces immunogenicity. Lower systemic exposure than semaglutide contributes to its lower efficacy ceiling.
Note(REWIND's broader CV label)
Semaglutide's SELECT trial enrolled patients with established CVD. Dulaglutide's REWIND enrolled patients with or at risk for cardiovascular disease — a broader population that includes primary prevention. That label distinction matters for which patients a cardiologist can justify prescribing it to, even as semaglutide dominates the overall market.
Trial data
AWARD trials (T2D): HbA1c reduction of 1.1–1.4%. Weight loss of ~3kg.
REWIND trial (cardiovascular outcomes): 12% reduction in MACE in T2D patients with or at risk for cardiovascular disease — notably including patients without established CVD, a broader inclusion than the LEADER and SUSTAIN cardiovascular trials, giving dulaglutide a differentiated CV label claim.
What to Expect
Week 1–2 — Generally milder GI side effects than twice-daily exenatide. Nausea is present but typically less intense than daily liraglutide.
Month 1–3 — Steady glycemic improvement in T2D patients. Weight loss is modest (~1–2kg this early).
Month 6+ — The ~3kg average weight loss range from AWARD trials reflects sustained but modest benefit. Stronger glycemic control than weight loss for most users.
Dosing and administration
0.75mg or 1.5mg weekly via single-dose pen with a hidden needle — one of the easier injection devices in the class, designed to reduce injection anxiety. No dose titration required for the 0.75mg starting dose. Can escalate to 3mg or 4.5mg for additional glycemic effect.
Development status
| Milestone | Status |
|---|---|
| Trulicity (T2D) | Approved US 2014 |
| Market position | Declining — Lilly's own tirzepatide outperforms it substantially |
| Pediatric use | Approved for T2D ≥10 years |
Safety profile
GI profile generally milder than twice-daily exenatide and broadly comparable to semaglutide, with lower discontinuation rates in some head-to-head trials. Same class warnings. No novel safety signals in post-marketing surveillance.
Who It's For
- Type 2 diabetes patients, particularly those with cardiovascular risk (REWIND label covers a broad CV population)
- People who are injection-averse — the autoinjector design is genuinely easier than most
- Patients stable on dulaglutide who want to discuss switching to tirzepatide for more weight loss
A provider conversation about whether tirzepatide makes sense as an upgrade is worth having if you're currently on dulaglutide primarily for weight.
Summary(The dulaglutide picture)
A well-designed once-weekly drug superseded clinically by tirzepatide from its own maker. The REWIND cardiovascular label — covering a broader population than SELECT — is the data point that outlasts its market relevance. Still prescribed in cost-sensitive settings and where tirzepatide formulary access lags.